Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Nov 2007:30 AM PST
-08:30 AM PST
Learn what truly sets the UC Riverside MBA apart and how it helps in your professional growth
Nov 2211:00 AM IST
-01:00 PM IST
Do RC/MSR passages scare you? e-GMAT is conducting a masterclass to help you learn – Learn effective reading strategies Tackle difficult RC & MSR with confidence Excel in timed test environment- Nov 23
11:00 AM IST
-01:00 PM IST
Attend this free GMAT Algebra Webinar and learn how to master the most challenging Inequalities and Absolute Value problems with ease. 
Nov 2510:00 AM EST
-11:00 AM EST
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors.
03 Sep 2023, 04:35
Kudos
Bookmarks
A) people who experience nausea are prone to discontinue use of the new drug prematurely
This option suggests that some patients might stop taking the new drug because of the mild nausea side effect. While this information is relevant, it does not directly address why the new drug is still preferable to the current one with occasional serious side effects. It does not provide a strong justification for choosing the new drug.
B) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it
This option introduces a possibility about the current drug having unidentified side effects. However, this does not directly address the argument's focus on why the new drug is preferable despite its more frequent side effects. It introduces uncertainty but doesn't make a strong case for the new drug's superiority.
C) other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug
This option introduces information about the prescription practices for other drugs but does not directly explain why the new drug is preferable. It doesn't address the comparison between the side effects of the new drug and the current one.
D) people who have received effective treatment for disease do not generally contract the disease again
This option discusses the effectiveness of treatment but doesn't directly address the comparison between the side effects of the new drug and the current one. It's not directly relevant to why the new drug is preferable.
E) there is a nonprescription medication that when taken with the new drug prevents the onset of nausea
This option provides a solution to the side effect problem associated with the new drug. If there is a nonprescription medication that can prevent nausea when taken alongside the new drug, it addresses the issue of frequent mild nausea and strengthens the argument for choosing the new drug despite its more frequent side effects. This option provides a direct justification for the new drug's preference.
Option (E) is the most logical choice as it directly addresses the concern of side effects and provides a solution, making it the best completion for the argument.
This option suggests that some patients might stop taking the new drug because of the mild nausea side effect. While this information is relevant, it does not directly address why the new drug is still preferable to the current one with occasional serious side effects. It does not provide a strong justification for choosing the new drug.
B) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it
This option introduces a possibility about the current drug having unidentified side effects. However, this does not directly address the argument's focus on why the new drug is preferable despite its more frequent side effects. It introduces uncertainty but doesn't make a strong case for the new drug's superiority.
C) other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug
This option introduces information about the prescription practices for other drugs but does not directly explain why the new drug is preferable. It doesn't address the comparison between the side effects of the new drug and the current one.
D) people who have received effective treatment for disease do not generally contract the disease again
This option discusses the effectiveness of treatment but doesn't directly address the comparison between the side effects of the new drug and the current one. It's not directly relevant to why the new drug is preferable.
E) there is a nonprescription medication that when taken with the new drug prevents the onset of nausea
This option provides a solution to the side effect problem associated with the new drug. If there is a nonprescription medication that can prevent nausea when taken alongside the new drug, it addresses the issue of frequent mild nausea and strengthens the argument for choosing the new drug despite its more frequent side effects. This option provides a direct justification for the new drug's preference.
Option (E) is the most logical choice as it directly addresses the concern of side effects and provides a solution, making it the best completion for the argument.
10 Nov 2023, 10:51
Kudos
Bookmarks
Understanding the argument - We need to strengthen the conclusion that "the new drug is clearly preferable" even in light of its drawbacks, which is mild nausea vis-a-vis the serious side effects of the "most commonly prescribed" such as seizures.
A DmitryFarber beautifully explained, option E, in a way, also takes away that mild side effect. If you see the argument in light of option E, then on one side, we have the "most commonly prescribed" drug leading to seizures, and on the other side, we have a new drug with practically no side effect (with the nonprescription medication to prevent nausea). Isn't it a no-brainer to choose the new drug in that case? That's why the author needs option E. For option B, it may also be possible that "the most prescribed drug" also leads to, say, vision loss, but how does it matter as we can also create such "n" possibilities for the new drug as well? It's good to stay within the scope of the argument: whether a new drug is better; why? Understanding the core of this argument is also very important from the business application perspective. Suppose you ask your team or your boss about A (which is what the conclusion asks us to strengthen), and the other side starts telling the drawbacks of B. Does it sound familiar?
So let's stick to the problem statement we are trying to solve, which is strengthening why the new drug is preferable.
A) people who experience nausea are prone to discontinue use of the new drug prematurely - out of scope.
B) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it - "other" side effects we don't care about for this argument. Out of scope.
C) other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug - "other" drugs out of scope. Please don't take it as a rule; wherever we see "other," we mark it wrong. Be cautious, as the GMAT is good at creating problems that can deceive us.. Understand the meaning.
D) people who have received effective treatment for disease do not generally contract the disease again - treatment by which drug is "the most commonly prescribed" or the new drug? Distortion.
E) there is a nonprescription medication that, when taken with the new drug, prevents the onset of nausea - ok.
A DmitryFarber beautifully explained, option E, in a way, also takes away that mild side effect. If you see the argument in light of option E, then on one side, we have the "most commonly prescribed" drug leading to seizures, and on the other side, we have a new drug with practically no side effect (with the nonprescription medication to prevent nausea). Isn't it a no-brainer to choose the new drug in that case? That's why the author needs option E. For option B, it may also be possible that "the most prescribed drug" also leads to, say, vision loss, but how does it matter as we can also create such "n" possibilities for the new drug as well? It's good to stay within the scope of the argument: whether a new drug is better; why? Understanding the core of this argument is also very important from the business application perspective. Suppose you ask your team or your boss about A (which is what the conclusion asks us to strengthen), and the other side starts telling the drawbacks of B. Does it sound familiar?
So let's stick to the problem statement we are trying to solve, which is strengthening why the new drug is preferable.A) people who experience nausea are prone to discontinue use of the new drug prematurely - out of scope.
B) It is possible that the drug now most commonly prescribed has side effects that have not yet been attributed to it - "other" side effects we don't care about for this argument. Out of scope.
C) other drugs for the disease have typically been prescribed only for patients allergic to the most commonly prescribed drug - "other" drugs out of scope. Please don't take it as a rule; wherever we see "other," we mark it wrong. Be cautious, as the GMAT is good at creating problems that can deceive us.
. Understand the meaning.D) people who have received effective treatment for disease do not generally contract the disease again - treatment by which drug is "the most commonly prescribed" or the new drug? Distortion.
E) there is a nonprescription medication that, when taken with the new drug, prevents the onset of nausea - ok.
17 Nov 2024, 03:48
Kudos
Bookmarks
Hello from the GMAT Club VerbalBot!
Thanks to another GMAT Club member, I have just discovered this valuable topic, yet it had no discussion for over a year. I am now bumping it up - doing my job. I think you may find it valuable (esp those replies with Kudos).
Want to see all other topics I dig out? Follow me (click follow button on profile). You will receive a summary of all topics I bump in your profile area as well as via email.
Thanks to another GMAT Club member, I have just discovered this valuable topic, yet it had no discussion for over a year. I am now bumping it up - doing my job. I think you may find it valuable (esp those replies with Kudos).
Want to see all other topics I dig out? Follow me (click follow button on profile). You will receive a summary of all topics I bump in your profile area as well as via email.
